According to the "China Fund News" report, last week the Fund conducted intensive research on 61 listed companies, and 7 listed companies were "grouped" by more than 5 funds. Companies in the rubber and plastic products industry have received greater attention.

Boya Biology has recently received market attention. On January 20, fund companies such as Fuanda, Fortune, Hongde, and HSBC Jinxin investigated Boya Bio. On January 21, nearly 30 fund companies such as Debon, Donghai, Fuanda, Fortune, and GF were surveyed. At the same time, many brokerages and private equity institutions participated in the survey. From the survey announcement, the blood product industry, company R&D status, fibrogen technology, international cooperation, pulp station resource status, blood product product price situation, etc. are the focus of the fund's attention.